Insights
Filter By
All Topics
Advocacy
Affordability
Analytics
Biosimilars
Commercialization
COVID-19
Data
Distribution
Engagement
Legislation
Market access
Medication adherence
Medication therapy management
Oncology
Patient care
Patient support services
Policy
Product access
Regulatory
Reimbursement
Research
Specialty pharmacy
Technology
Third-party logistics
Sort By
Date (Newest to Oldest)
Date (Oldest to Newest)
Title (A-Z)
Title (Z-A)
Filter
Innomar Strategies
Drug development checklist: what to look for in a commercialization partner
Innomar Strategies
April 2024
Manufacturers
Pre-launch checklist: what to look for in a commercialization partner
Innomar Strategies
April 2024
Manufacturers
Post launch checklist: what to look for in a commercialization partner
Innomar Strategies
April 2024
Manufacturers
InnomarLive 2023: Part One
Innomar Strategies
April 2023
Manufacturers
InnomarLive 2023: Part Two
Innomar Strategies
April 2023
Manufacturers
InnomarLive 2023: Part Three
Innomar Strategies
April 2023
Manufacturers
Regulatory Services: Management and Control of Certified Product Information Document
Innomar Strategies
August 2022
Manufacturers
Webinar: Impact of COVID-19 on Patient Support Programs in Canada
Innomar Strategies
June 2021
Manufacturers
Case Study: A proven approach for an emerging specialty pharma company
Innomar Strategies
April 2021
Manufacturers
Case Study: A flexible solution for launching a new molecule in oncology
Innomar Strategies
April 2021
Manufacturers
Case Study: Launching a new molecule for a rare disease
Innomar Strategies
April 2021
Manufacturers
The value of Real-World Evidence in Canadian drug commercialization: Part 2
Innomar Strategies
April 2021
Manufacturers
Webinar: Utilizing Real World Evidence Across the Product Life Cycle
Innomar Strategies
June 2020
Manufacturers
Regulatory Services: Submission Filing
Anne Tomalin
Quality, Regulatory & Safety
May 2020
Manufacturers
Regulatory Services: Submission and Product Lifecycle Considerations
Anne Tomalin
Quality, Regulatory & Safety
May 2020
Manufacturers
Regulatory Services: How are products approved?
Anne Tomalin
Quality, Regulatory & Safety
May 2020
Manufacturers
Regulatory Services: Navigating Clinical Trial applications
Anne Tomalin
Quality, Regulatory & Safety
May 2020
Manufacturers
Commercializing in Canada: Quality Assurance and GMP Services
Innomar Strategies
April 2020
Manufacturers
Commercializing in Canada: Regulatory Publishing and Submissions
Innomar Strategies
April 2020
Manufacturers
Webinar: Health Canada’s Regulatory and Quality approach to addressing COVID-19 challenges
Innomar Strategies
April 2020
Manufacturers
Why Canada: Leveraging our partnerships and relationships to assist in your launch strategy.
Sandra Anderson
Commercialization and Strategy
March 2020
Manufacturers
Why Canada: How we help Pharmaceutical Manufacturers commercialize their products in Canada.
Sandra Anderson
Commercialization and Strategy
February 2020
Manufacturers
Why Canada: Is Canada an attractive market for global pharmaceutical manufacturers?
Sandra Anderson
Commercialization and Strategy
January 2020
Manufacturers
InnomarLive 2019: Commercializing in Canada
Innomar Strategies
December 2019
Explore More by Topic
Advocacy
Affordability
Analytics
Biosimilars
Commercialization
COVID-19
brand="Cencora" culture="EN" env="Development" tracker="False"
